Cargando…
Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis
OBJECTIVE: The prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis (NAFLD/NASH) is increasing. NAFLD/NASH may progress to cirrhosis and hepatocellular carcinoma. However, most patients with NAFLD/NASH will die from a vascular cause. There are no approved pharmacological...
Autores principales: | Mahjoubin-Tehran, Maryam, De Vincentis, Antonio, Mikhailidis, Dimitri P., Atkin, Stephen L., Mantzoros, Christos S., Jamialahmadi, Tannaz, Sahebkar, Amirhossein |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8324680/ https://www.ncbi.nlm.nih.gov/pubmed/32673798 http://dx.doi.org/10.1016/j.molmet.2020.101049 |
Ejemplares similares
-
Harnessing the Therapeutic Potential of Decoys in Non-Atherosclerotic Cardiovascular Diseases: State of the Art
por: Mahjoubin-Tehran, Maryam, et al.
Publicado: (2021) -
The Emerging Role of Nanomedicine in the Management of Nonalcoholic Fatty Liver Disease: A State-of-the-Art Review
por: Moosavian, Seyedeh Alia, et al.
Publicado: (2021) -
Association between Thyroid Hormones and Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis in Obese Individuals Undergoing Bariatric Surgery
por: Ashraf Ganjooei, Narges, et al.
Publicado: (2022) -
The Role of Lipid Profile as an Independent Predictor of Non-alcoholic Steatosis and Steatohepatitis in Morbidly Obese Patients
por: Ganjooei, Narges Ashraf, et al.
Publicado: (2021) -
Target Deconvolution of Fenofibrate in Nonalcoholic Fatty Liver Disease Using Bioinformatics Analysis
por: Mahmoudi, Ali, et al.
Publicado: (2021)